John Allan, MD, presents and reviews the case of a 67-year-old man with chronic lymphocytic leukemia.
A 67-Year-Old Man with Chronic Lymphocytic Leukemia
A key opinion leader shares insight into testing and risk stratification for chronic lymphocytic leukemia.
John Allan, MD, highlights treatment options in the first-line setting for chronic lymphocytic leukemia.
A leukemia specialist details the Resonate-2 clinical trial studying BTK inhibitor ibrutinib.
John Allan, MD, compares the available approved BTK inhibitors for treating chronic lymphocytic leukemia.
An expert describes various treatment approaches for patients with high-risk chronic lymphocytic leukemia.
John Allan, MD, looks to the future of chronic lymphocytic leukemia treatments.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
